DataMeds AI Regains Nasdaq Compliance After Equity Restoration
Tampa, Fla., Oct. 20, 2026. DataMeds AI, Inc. (NASDAQ: MEDS) has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Rule, after receiving a notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC dated October 19, 2026. The company met the requirement to maintain a minimum stockholders’ equity of $2.5 million, a threshold it previously failed to satisfy.
Tampa, Fla., Oct. 20, 2026. DataMeds AI, Inc. (NASDAQ: MEDS) has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Rule, after receiving a notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC dated October 19, 2026. The company met the requirement to maintain a minimum stockholders’ equity of $2.5 million, a threshold it previously failed to satisfy.
DataMeds AI originally received a notice of delisting from Nasdaq on April 13, 2026, citing two grounds: failure to meet the minimum $1.00 bid-price and failure to maintain $2,500,000 in stockholders’ equity. On June 9, 2026, Nasdaq notified the company that it had regained bid-price compliance and granted additional time to address the equity shortfall.
The path to full compliance was confirmed through two recent filings. A Form 8-K filed on October 13, 2026, stated that the company’s stockholders’ equity exceeded $2,500,000. A subsequent Form 8-K filed on October 16, 2026, provided details on the material events that resulted in the equity exceeding the required level. Based on these filings, Nasdaq confirmed compliance on October 19, 2026.
The company noted that if it fails to evidence compliance upon filing its next periodic report, it may be subject to delisting proceedings.
DataMeds AI is a healthcare company headquartered in Tampa, Fla., that integrates Health IT and physical infrastructure with its EinsteinRx super intelligence platform and PharmacyChain smart contracts platform. The company operates the Health Lives Here mobile application and Corexa Pharmacy, which provides dispensing services and distributes products from Tollo Health. DataMeds secured licensed rights to REBOOT’s patented GLP-1 patient management technology; REBOOT is a subsidiary of Data Health Partners. Its subsidiary Helomics Corporation operates a CLIA-certified laboratory in Pittsburgh offering the ChemoFx Assay.
The press release includes forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements cover anticipated business strategies, operating plans, growth opportunities, and the company’s ability to maintain Nasdaq compliance and fund operations. They also reference the development of proprietary blockchain features, the creation of a pharmacy network, and an anticipated partnership with NFL Alumni Health. The release mentions a proposed transaction with DataVault AI Inc. (NASDAQ: DVLT), Scilex Holding Company, EOS Holdings, and HealthBridge Advisors. Actual results may differ materially from these statements due to risks described in the company’s most recent Annual Report on Form 10-K and subsequent SEC filings.